Cerebellin 4, a synaptic protein, enhances inhibitory activity and resistance of neurons to amyloid-β toxicity

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 1057-1071

  Chacón, Pedro J ^a,c   del Marco, Ángel ^a   Arévalo, Ángeles ^b   Domínguez Giménez, Paloma ^a   García Segura, Luis Miguel ^b   Rodríguez Tébar, Alfredo ^a  

^a CSIC   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid ; Cerebellin 4; Hes1; Hippocampus; NGF

Indexed keywords

AMYLOID BETA PROTEIN; CEREBELLIN 4; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; VESICULAR INHIBITORY AMINO ACID TRANSPORTER; 4 AMINOBUTYRIC ACID RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CEREBELLIN 4 PRECURSOR, MOUSE; HES1 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; NERVE PROTEIN; PROTEIN PRECURSOR;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CBLN4 GENE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITE; DENTATE GYRUS; DOWN REGULATION; GABAERGIC SYSTEM; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HES1 GENE; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NERVE CELL GROWTH; NONHUMAN; PERIKARYON; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRAMIDAL LAYER; PYRAMIDAL NERVE CELL; STRATUM LACUNOSUM MOLECULARE; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; NERVE CELL PLASTICITY; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CA1 REGION, HIPPOCAMPAL; CELLS, CULTURED; GABAERGIC NEURONS; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; PROTEIN PRECURSORS;

EID: 84922844206     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.11.006     Document Type: Article

References (50)

1. Arevalo M.A., Roldan P.M., Chacon P.J., Rodriguez-Tebar A. Amyloid β serves as an NGF-like neurotrophic factor or acts as a NGF antagonist depending on its concentration. J.Neurochem. 2009, 111:1425-1433.
2. Berke B., Wittnam J., McNeill E., Van Vactor D.L., Keshishian H. Retrograde BMP signaling at the synapse: a permissive signal for synapse maturation and activity-dependent plasticity. J.Neurosci. 2013, 33:17937-17950.
3. Borlongan C.V. Recent preclinical evidence advancing cell therapy for Alzheimer's disease. Exp. Neurol. 2012, 237:142-146.
4. Brady D.R., Mufson E.J. Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain. Neuroscience 1997, 80:1113-1125.
5. Chacon P.J., Arevalo M.A., Tebar A.R. NGF-activated protein tyrosine phosphatase 1B mediates the phosphorylation and degradation of I-kappa-Balpha coupled to NF-kappa-B activation, thereby controlling dendrite morphology. Mol. Cell Neurosci. 2010, 43:384-393.
6. Chacon P.J., Garcia-Mejias R., Rodriguez-Tebar A. Inhibition of RhoA GTPase and the subsequent activation of PTP1B protects cultured hippocampal neurons against amyloid β toxicity. Mol. Neurodegener. 2011, 6:14.
7. Chacon P.J., Rodriguez-Tebar A. Increased expression of the homologue of enhancer-of-split 1 protects neurons from β amyloid neurotoxicity and hints at an alternative role for transforming growth factor β1 as a neuroprotector. Alzheimers Res. Ther. 2012, 4:31.
8. Cobb S.R., Buhl E.H., Halasy K., Paulsen O., Somogyi P. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature 1995, 378:75-78.
9. Ding X., Li Y., Liu Z., Zhang J., Cui Y., Chen X., Chopp M. The sonic hedgehog pathway mediates brain plasticity and subsequent functional recovery after bone marrow stromal cell treatment of stroke in mice. J.Cereb. Blood Flow Metab. 2013, 33:1015-1024.
10. Donato F., Rompani S.B., Caroni P. Parvalbumin-expressing basket-cell network plasticity induced by experience regulates adult learning. Nature 2013, 504:272-276.
11. Eiberger B., Schilling K. Cerebellins: capstones to bridge the synaptic cleft. J.Neurochem. 2012, 121:697-699.
12. Fath T., Ke Y.D., Gunning P., Gotz J., Ittner L.M. Primary support cultures of hippocampal and substantia nigra neurons. Nat. Protoc. 2009, 4:78-85.
13. Freund T.F., Buzsaki G. Interneurons of the hippocampus. Hippocampus 1996, 6:347-470.
14. Freund T.F., Katona I. Perisomatic inhibition. Neuron 2007, 56:33-42.
15. Gomez-Isla T., Price J.L., McKeel D.W., Morris J.C., Growdon J.H., Hyman B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J.Neurosci. 1996, 16:4491-4500.
16. Goslin K., Banker G. Experimental observations on the development of polarity by hippocampal neurons in culture. J.Cell Biol. 1989, 108:1507-1516.
17. Haddick P.C., Tom I., Luis E., Quinones G., Wranik B.J., Ramani S.R., Stephan J.P., Tessier-Lavigne M., Gonzalez L.C. Defining the ligand specificity of the deleted in colorectal Cancer (DCC) receptor. PLoS One 2014, 9:e84823.
18. Hirai H., Pang Z., Bao D., Miyazaki T., Li L., Miura E., Parris J., Rong Y., Watanabe M., Yuzaki M., Morgan J.I. Cbln1 is essential for synaptic integrity and plasticity in the cerebellum. Nat. Neurosci. 2005, 8:1534-1541.
19. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
20. Ito-Ishida A., Miura E., Emi K., Matsuda K., Iijima T., Kondo T., Kohda K., Watanabe M., Yuzaki M. Cbln1 regulates rapid formation and maintenance of excitatory synapses in mature cerebellar Purkinje cells invitro and invivo. J.Neurosci. 2008, 28:5920-5930.
21. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001, 17:157-165.
22. Jimenez S., Torres M., Vizuete M., Sanchez-Varo R., Sanchez-Mejias E., Trujillo-Estrada L., Carmona-Cuenca I., Caballero C., Ruano D., Gutierrez A., Vitorica J. Age-dependent accumulation of soluble amyloid β (Aβ) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3β pathway in Alzheimer mouse model. J.Biol. Chem. 2011, 286:18414-18425.
23. Johansson T., Lejonklou M.H., Ekeblad S., Stalberg P., Skogseid B. Lack of nuclear expression of hairy and enhancer of split-1 (HES1) in pancreatic endocrine tumors. Horm. Metab. Res. 2008, 40:354-359.
24. Kim J., Nadal M.S., Clemens A.M., Baron M., Jung S.C., Misumi Y., Rudy B., Hoffman D.A. Kv4 accessory protein DPPX (DPP6) is a critical regulator of membrane excitability in hippocampal CA1 pyramidal neurons. J.Neurophysiol. 2008, 100:1835-1847.
25. Kullmann D.M. Interneuron networks in the hippocampus. Curr. Opin. Neurobiol. 2011, 21:709-716.
26. Lemere C.A. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol. Neurodegener. 2013, 8:36.
27. Limon A., Reyes-Ruiz J.M., Miledi R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10071-10076.
28. Matsuda K., Miura E., Miyazaki T., Kakegawa W., Emi K., Narumi S., Fukazawa Y., Ito-Ishida A., Kondo T., Shigemoto R., Watanabe M., Yuzaki M. Cbln1 is a ligand for an orphan glutamate receptor delta2, a bidirectional synapse organizer. Science 2010, 328:363-368.
29. Miles R., Toth K., Gulyas A.I., Hajos N., Freund T.F. Differences between somatic and dendritic inhibition in the hippocampus. Neuron 1996, 16:815-823.
30. Ota M.S., Kaneko Y., Kondo K., Ogishima S., Tanaka H., Eto K., Kondo T. Combined in silico and invivo analyses reveal role of Hes1 in taste cell differentiation. PLoS Genet. 2009, 5:e1000443.
31. Rafii M.S., Baumann T.L., Bakay R.A., Ostrove J.M., Siffert J., Fleisher A.S., Herzog C.D., Barba D., Pay M., Salmon D.P., Chu Y., Kordower J.H., Bishop K., Keator D., Potkin S., Bartus R.T. Aphase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014, 10:571-581.
32. Rissman R.A., De Blas A.L., Armstrong D.M. GABA(A) receptors in aging and Alzheimer's disease. J.Neurochem. 2007, 103:1285-1292.
33. Rissman R.A., Mobley W.C. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J.Neurochem. 2011, 117:613-622.
34. Salama-Cohen P., Arevalo M.A., Grantyn R., Rodriguez-Tebar A. Notch and NGF/p75NTR control dendrite morphology and the balance of excitatory/inhibitory synaptic input to hippocampal neurones through Neurogenin 3. J.Neurochem. 2006, 97:1269-1278.
35. Salama-Cohen P., Arevalo M.A., Meier J., Grantyn R., Rodriguez-Tebar A. NGF controls dendrite development in hippocampal neurons by binding to p75NTR and modulating the cellular targets of Notch. Mol. Biol. Cell 2005, 16:339-347.
36. Simon-Areces J., Membrive G., Garcia-Fernandez C., Garcia-Segura L.M., Arevalo M.A. Neurogenin 3 cellular and subcellular localization in the developing and adult hippocampus. J.Comp. Neurol. 2010, 518:1814-1824.
37. Slemmon J.R., Blacher R., Danho W., Hempstead J.L., Morgan J.I. Isolation and sequencing of two cerebellum-specific peptides. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6866-6870.
38. Sloviter R.S. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987, 235:73-76.
39. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. Article 3.
40. Sopova K., Gatsiou K., Stellos K., Laske C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. Curr. Alzheimer Res. 2014, 11:27-39.
41. Stavoe A.K., Colon-Ramos D.A. Netrin instructs synaptic vesicle clustering through Rac GTPase, MIG-10, and the actin cytoskeleton. J.Cell Biol 2012, 197:75-88.
42. Takahashi H., Brasnjevic I., Rutten B.P., Van Der K.N., Perl D.P., Bouras C., Steinbusch H.W., Schmitz C., Hof P.R., Dickstein D.L. Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease. Brain Struct. Funct. 2010, 214:145-160.
43. Trevino V., Falciani F., Barrera-Saldana H.A. DNA microarrays: a powerful genomic tool for biomedical and clinical research. Mol. Med. 2007, 13:527-541.
44. Tuszynski M.H. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007, 21:179-189.
45. Tuszynski M.H., Thal L., Pay M., Salmon D.P., HS U., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., Conner J. Aphase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11:551-555.
46. Uemura T., Lee S.J., Yasumura M., Takeuchi T., Yoshida T., Ra M., Taguchi R., Sakimura K., Mishina M. Trans-synaptic interaction of GluRdelta2 and Neurexin through Cbln1 mediates synapse formation in the cerebellum. Cell 2010, 141:1068-1079.
47. Verret L., Mann E.O., Hang G.B., Barth A.M., Cobos I., Ho K., Devidze N., Masliah E., Kreitzer A.C., Mody I., Mucke L., Palop J.J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149:708-721.
48. Wei P., Pattarini R., Rong Y., Guo H., Bansal P.K., Kusnoor S.V., Deutch A.Y., Parris J., Morgan J.I. The Cbln family of proteins interact with multiple signaling pathways. J.Neurochem. 2012, 121:717-729.
49. West M.J., Coleman P.D., Flood D.G., Troncoso J.C. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994, 344:769-772.
50. Wettenhall J.M., Simpson K.M., Satterley K., Smyth G.K. affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics 2006, 22:897-899.